paclitaxel has been researched along with Carcinosarcoma in 56 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (1.79) | 18.2507 |
2000's | 9 (16.07) | 29.6817 |
2010's | 35 (62.50) | 24.3611 |
2020's | 11 (19.64) | 2.80 |
Authors | Studies |
---|---|
Bonamino, MH; Chaves, CBP; da Silva, JL; de Albuquerque, LZ; de Melo, AC; de Mesquita, GG; Rodrigues, FR | 1 |
Clarke, A; Day, E; de la Rosa, CN; Fiorentino, F; Krell, J; Reddi, M; Webber, L | 1 |
Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP | 1 |
Matei, D; Roque, DR | 1 |
Wang, PH; Yang, ST | 1 |
Crane, E | 1 |
Bijlsma, RM; Franken, MD; Röckmann-Helmbach, H | 1 |
Mandilaras, V; Park, CL; Rajadurai, CV; Ton Nu, TN | 1 |
Fujiwara, Y; Ishikawa, M; Kato, T; Kojima, Y; Nishikawa, T; Noguchi, E; Ohtake, Y; Okuma, H; Seo, T; Shimomura, A; Sudo, K; Tamura, K; Tanioka, M; Uehara, T; Uno, M; Yonemori, K | 1 |
Economos, K; Friedman, M; Gorelick, C; Heyman, T; Kanis, MJ; Lee, YC; McEachron, J; Shanahan, L; Singhal, PK; Tran, V | 1 |
Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
Aoyama, Y; Harada, H; Hoshino, K; Kagami, S; Kinjo, Y; Kuradome, Y; Murakami, M; Ueda, T; Yoshino, K | 1 |
Adachi, S; Baba, T; Blake, EA; Bush, SH; Hasegawa, K; Ikeda, Y; Im, DD; Iwasaki, K; Johnson, MS; Kelley, JL; Klobocista, MM; Machida, H; Matsuo, K; Miyake, TM; Nagano, T; Nishimura, M; Omatsu, K; Pejovic, T; Roman, LD; Ross, MS; Satoh, S; Shahzad, MMK; Shida, M; Takano, T; Takekuma, M; Takeuchi, S; Ueda, Y; Ueland, FR; Yanai, S; Yokoyama, T; Yunokawa, M | 1 |
Brackmann, M; Erba, J; McLean, K; Reynolds, RK; Stasenko, M; Uppal, S | 1 |
Chang, CW; Chen, CH; Cheng, CJ; Chiu, YH; Fu, HS; Liu, WM; Wang, ID; Wu, YC | 1 |
Bryant, A; Das, N; Galaal, K; Godfrey, K; Kucukmetin, A; Lopes, AD; Naik, R; van der Heijden, E | 1 |
Altundağ, Ö; Ayhan, A; Dizdar, O; Dursun, P; Kucukoztas, N; Ozen, O; Rahatli, S; Reyhan, NH; Tarhan, C; Yalcin, S; Yildiz, F | 1 |
Baba, T; Konishi, I; Mandai, M; Matsumura, N; Mikami, Y; Takamatsu, S | 1 |
Izuta, C; Kaseki, H; Matsuura, T; Otsuka, I; Sato, M; Suzuki, Y; Takagi, K; Takaya, H; Tanaka, A | 1 |
Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
Fujimoto, T; Ito, K; Kagabu, M; Kigawa, J; Kurachi, H; Matsumoto, T; Mizunuma, H; Nagase, S; Nakahara, K; Niikura, H; Nishiyama, H; Otsuki, T; Sato, N; Sato, S; Shimada, M; Shoji, T; Soeda, S; Sugiyama, T; Takano, T; Tase, T; Terada, Y; Tokunaga, H; Toyoshima, M; Utsunomiya, H; Yaegashi, N; Yamada, H; Yokoyama, Y | 1 |
Borger, D; Bradford, LS; Clark, RM; Foster, R; Groeneweg, JW; Growdon, WB; Rauh-Hain, A; Rueda, BR; Zhang, L; Zukerberg, LR | 1 |
Ditto, A; Lorusso, D; Mancini, M; Martinelli, F; Raspagliesi, F; Sarno, I | 1 |
Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
Arakawa, A; Futagami, M; Kamoi, S; Katabuchi, H; Katsuta, T; Kotera, K; Kudaka, W; Nishiyama, H; Nomura, H; Otsuki, A; Sato, N; Shibata, K; Shimada, M; Watanabe, Y; Yaegashi, N; Yokoyama, Y | 1 |
Becker, MA; Enderica-Gonzalez, S; Glaser, G; Haluska, P; Harrington, SC; Hou, X; Weroha, SJ | 1 |
Chu, C; Lin, LL; Rubin, S; Xu, MJ | 1 |
Dickson, EL; Dottino, J; Fader, AN; Gehrig, PA; Geller, MA; Havrilesky, L; Pierce, S; Ricci, S; Secord, AA; Vogel, RI | 1 |
Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
Hazan, E; Sahu, J; Santa, E | 2 |
Economopoulos, T; Panayiotides, J; Papachristodoulou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Sykiotis, C; Tountas, N; Xiros, N | 1 |
Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q | 1 |
A'Hern, R; Ang, JE; Blake, P; Coombes, I; Everard, M; Gabra, H; Gore, ME; Hall, G; Jenkins, A; Jones, RL; Kaye, SB; Keyzor, C; Shah, RN; Thomas, K | 1 |
Bond, VK; Im, DD; Matsuo, K; Rosenshein, NB | 1 |
Degeest, K; Filiaci, VL; Hanjani, P; Mannel, RS; Miller, BE; Powell, MA; Rose, PG; Susumu, N; Ueland, FR | 1 |
Fujiwara, K; Kamiura, S; Masuhara, K; Miyoshi, A; Ohta, Y; Okazawa, M; Tomita, Y; Yoshino, K | 1 |
Atkinson, EN; Brown, J; Burke, TW; Coleman, RL; Euscher, E; Gano, JB; Lacour, RA; Ramirez, PT; Ramondetta, LM; Sun, CC | 1 |
Kagami, S; Mori, M; Namba, Y; Sugano, T; Uenami, T; Yokota, S | 1 |
Balakrishnan, K; Natarajaseenivasan, K; SenthilKumar, G; Shanmughapriya, S; Vasanthi, N; Vinodhini, K | 1 |
Camporeale, A; Cormio, G; De Mitri, P; Falagario, M; Loizzi, V; Putignano, G; Scardigno, D; Selvaggi, LE | 1 |
Choijamts, B; Emoto, M; Iwasaki, H; Jimi, S; Kondo, T; Kuroki, M; Matsumoto, T; Naganuma, Y | 1 |
Chun, KC; Kim, DY; Kim, JH; Kim, JJ; Kim, YM; Kim, YT; Nam, JH | 1 |
Bellone, S; Carrara, L; Emiliano, C; Guzzo, F; Pecorelli, S; Roque, DM; Rutherford, TJ; Santin, AD; Sartori, E; Schwartz, PE | 1 |
Chang, CC; Wu, CC | 1 |
Amant, F; Neven, P; Vandenput, I; Vergote, I | 1 |
Aynaoglu, G; Kahraman, K; Kankaya, D; Ortac, F | 1 |
Aghajanian, C; Powell, MA; Secord, AA; Sill, MW; Steinhoff, M | 1 |
Kang, S; Lim, MC; Lim, S; Park, JY; Park, SY; Seo, SS; Yoo, HJ | 1 |
Akahira, J; Ito, K; Matsunaga, G; Niikura, H; Tase, T; Toyoshima, M; Yaegashi, N | 1 |
Gold, MA; Huh, WK; Johnson, GA; Lewin, SN; Mannel, RS; McMeekin, DS; Mutch, DG; Powell, MA; Rutledge, TL; Walker, JL | 1 |
Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR | 1 |
Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Rodriguez, GC; Secord, AA; Soper, JT | 1 |
Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S | 1 |
Carriero, C; Cormio, G; Di Vagno, G; Fontana, A; Greco, P; Loverro, G; Melilli, GA; Selvaggi, L | 1 |
Blessing, JA; Curtin, JP; DeGeest, K; Soper, JT | 1 |
7 review(s) available for paclitaxel and Carcinosarcoma
Article | Year |
---|---|
Beyond Serous: Treatment Options for Rare Endometrial Cancers.
Topics: Carboplatin; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Lymph Node Excision; Paclitaxel | 2022 |
An Unconventional Regimen of Carboplatin and Paclitaxel in Metastatic Colorectal Carcinosarcoma: A Case Report and Review of Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Colorectal Neoplasms; Female; Humans; Paclitaxel | 2023 |
Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Drug Hypersensitivity; Drug Substitution; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Neoplasms | 2021 |
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Paclitaxel; Radiotherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2013 |
[Carcinosarcoma of the ovary treated with paclitaxel and carboplatin chemotherapy - a report of 4 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2013 |
Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Humans; Ifosfamide; Middle Aged; Mucin-1; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Chemotherapy in the treatment of ovarian carcinosarcoma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 1999 |
12 trial(s) available for paclitaxel and Carcinosarcoma
Article | Year |
---|---|
Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2022 |
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Uterine Neoplasms | 2022 |
Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Uterine Neoplasms; Uterus | 2014 |
Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Uterine Neoplasms | 2015 |
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2009 |
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinosarcoma; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Program Evaluation; Risk Assessment; Survival Analysis; Treatment Outcome; Uterine Neoplasms | 2010 |
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2011 |
Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies | 2012 |
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2012 |
Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Sarcoma, Endometrial Stromal; Uterine Neoplasms | 2012 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Treatment Outcome; United States; Uterine Neoplasms | 2007 |
Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinosarcoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2001 |
37 other study(ies) available for paclitaxel and Carcinosarcoma
Article | Year |
---|---|
The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma.
Topics: Aged; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Carboplatin; Carcinosarcoma; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; Middle Aged; Paclitaxel; Prevalence; Prognosis; Programmed Cell Death 1 Receptor; Signal Transduction; Tumor Microenvironment; Uterine Neoplasms | 2021 |
Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Paclitaxel; Uterine Neoplasms | 2022 |
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Ifosfamide; Paclitaxel; Uterine Neoplasms | 2022 |
[An exceptional venous pattern in a patient with cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Paclitaxel | 2023 |
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Disease-Free Survival; Female; Humans; Ifosfamide; Paclitaxel; Retrospective Studies | 2019 |
Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinosarcoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salpingo-oophorectomy; Survival Rate; Uterine Neoplasms | 2020 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2018 |
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2018 |
Primary peritoneal carcinosarcoma: A report of two cases.
Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Fatal Outcome; Female; Humans; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms | 2019 |
Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carboplatin; Carcinosarcoma; Cross-Linking Reagents; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Turkey; Uterine Neoplasms | 2013 |
Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinosarcoma; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Hypercalcemia; Hysterectomy; Ovariectomy; Paclitaxel; Paraneoplastic Syndromes; Salpingectomy; Treatment Outcome; Uterine Hemorrhage; Uterine Neoplasms; Uterus | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Class I Phosphatidylinositol 3-Kinases; Endometrial Neoplasms; Female; Humans; Mice; Mice, SCID; Morpholines; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Uterine Neoplasms | 2014 |
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease Models, Animal; Female; Gene Expression Profiling; Humans; Maximum Tolerated Dose; Mice; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden | 2017 |
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Uterine Neoplasms | 2015 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Diffuse Rash After the Administration of Carboplatin and Paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinosarcoma; Drug Eruptions; Eczema; Exanthema; Female; Humans; Middle Aged; Paclitaxel; Skin; Uterine Neoplasms | 2016 |
Diffuse Rash After the Administration of Carboplatin and Paclitaxel: Answer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinosarcoma; Drug Eruptions; Eczema; Exanthema; Female; Humans; Middle Aged; Paclitaxel; Skin; Uterine Neoplasms | 2016 |
Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Survival Rate; Uterine Neoplasms | 2008 |
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2008 |
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2010 |
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinosarcoma; Endometrium; Female; Humans; Ifosfamide; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel | 2011 |
[A case of sarcomatoid carcinoma of the lung successfully treated with carboplatin, paclitaxel and bevacizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinosarcoma; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2011 |
Bilateral ovarian teratoma complicated with carcinosarcoma in a 68 year old woman: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Teratoma | 2011 |
CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Topics: AC133 Antigen; Animals; Antigens, CD; Antigens, Neoplasm; Carcinosarcoma; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Separation; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Estrogen Receptor beta; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glycoproteins; Homeodomain Proteins; Humans; Immunohistochemistry; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mixed Tumor, Mullerian; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; PAX2 Transcription Factor; Peptides; SOXB1 Transcription Factors; Uterine Neoplasms; Vimentin; Wnt4 Protein | 2011 |
Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis | 2011 |
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinosarcoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Inhibitory Concentration 50; Middle Aged; Ovarian Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; Tubulin; Uterine Neoplasms | 2012 |
Beau's lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Humans; Ifosfamide; Middle Aged; Nail Diseases; Paclitaxel; Pigmentation Disorders; Renal Dialysis; Uterine Neoplasms | 2013 |
Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Chordoma; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Sacrococcygeal Region; Uterine Neoplasms | 2012 |
Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2004 |
Carcinosarcoma of the ovary-a case series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2006 |
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; North Carolina; Paclitaxel; Pilot Projects; Treatment Outcome; Utah; Uterine Cervical Neoplasms | 2007 |
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2008 |